Learn from our biopharma experts, explore stimulating thought leadership and see some of our clients’ past successes.
blog post

Disruptors in the PsO and PsA Market: Weighing Clearance, Convenience and Cost

By: Vania Galarraga, MPH, Engagement ManagerSkin diseases constitute one of the leading causes of health burden worldwide, measured as disability-adjusted life years (DALYs). Among skin diseases, psoriasis (PsO) carries the third-largest disability weight, which translates into health loss and poor quality of life (QoL)1. Globally, approximately 1-8% of the population suffers from PsO2, 3. Among PsO p[...]

blog post

EGFR-Mutation-Positive NSCLC: Choosing the Best Therapeutic Strategy

By: Nick Turner, PhD, Senior Director Activating mutations in the EGFR gene are found in about 10-12% of all non-small cell lung cancer (NSCLC) cases and around 50% of cases in East-Asian patients. Cancer in patients with mutations is driven by constitutive activation of EGFR-signaling pathways due to acquired mutations in the catalytic domain of the receptor rendering them amenable to EGFR-tyrosine kinase[...]

blog post

Checkpoint Inhibitors: Changing the Treatment Paradigm in Metastatic NSCLC

By: Nick Turner, PhD, Senior DirectorLung cancer is the leading cause of cancer mortality worldwide, accounting for more than 1.6 million deaths annually. Non-small cell lung cancer (NSCLC) accounts for 85% of all new cases. Current first-line treatment decisions for metastatic NSCLC mandate analysis of the genetic status of the cancer to determine the presence of driver mutations, such as activating mutat[...]

blog post

New Paradigms in the Treatment of Breast Cancer

By: Nick Turner, PhD and Paula Palacios Fernandez, MScBreast cancer is the most common cancer in women with more than 2.1 million new cases diagnosed in 2018. And with more than 600,000 deaths in 2018, it is the second-leading cause of cancer deaths in women worldwide (WHO). Advances have been made across all stages and sub-types of the disease and provide hop[...]

white paper

CAR-T: Advancing the Path for Clinical and Commercial Success

By: Ben Doran, Stuart Crichton, Ben Druck and Vasiliki Patsioura.The Prescient team has prepared a white paper discussing our view on the recent advances in the CAR-T landscape. In this paper, we do not focus on the already well-documented challenges, but rather present ou[...]

blog post

Early Mortality Risk in Trials of Checkpoint Inhibitors

By: Nick Turner, PhDA largely glossed-over finding from active-controlled trials of checkpoint inhibitors in solid tumors is the delayed crossover of Kaplan-Meier (K-M) survival curves, consistent with increased risk of disease progression and mortality early in checkpoint inhibitor immunotherapy (CPI). This raises the heretical proposition that CPI monotherapy may have a detrimental effect on progression an[...]

case study

Strategic Brand Planning: Winning by Resource Optimization

Our client was a global biopharmaceutical company with a market-leading brand more than 20 years’ old. It came under intense pricing pressure due to generic entries from companies known to play primarily on price.

case study

Mature Brand Planning: Specialty Product Late Life Cycle Management Strategy

Our global pharmaceutical client had a product whose patent was expiring within a year. The client wanted to understand the potential impact of generic competition on its brand in key revenue markets. Prescient was engaged to develop tactics to defend market share in these markets by:

case study

Net Present Value: Assessing Opportunities for Indication Expansion

Our client, a European specialty pharmaceutical company, was considering an expansion of indications within its target therapeutic group via licensing and acquiring products that were in clinical development, soon-to-be-launched or already marketed.